Pediatric Hematology/Oncology

Endocrinology

Questions discussed in this category

Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?

How would you counsel a female to male transgender patient regarding VTE risk with testosterone therapy, who has additional mild-moderate risk factors for thrombosis?

Additional risk factors could be family history of VTE or thrombophilia, such as antithrombin deficiency.

1 Answer available

Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?

2 Answers available

How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?

4 Answers available

How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?

1 Answer available

In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?

No prior thrombosis; no family history of thrombosis. As per endocrine, the only useful therapy for the osteoporosis is estrogen.

1 Answer available

Are there contraindications to growth hormone therapy in patients who have completed treatment for pediatric cancer?

1 Answer available

When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?

If so, how often do you check these labs?

1 Answer available

What recommendations do you have for a transgender female patient with history of prothrombin gene mutation who is interested in starting gender affirming hormone therapy?

The patient has no personal history of VTE, but has positive family history of VTE. Any prophylactic anticoagulation options? How would manage...

1 Answer available

How do you incorporate denosumab into the surgical management of giant cell tumor of bone?

Does the degree of resectability affect your management?

2 Answers available

How do you counsel male-to-female transgender patients on the VTE risk of hormonal therapy?

1 Answer available

Papers discussed in this category

BMJ, 2008 May 20

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.

Circulation,

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.

Endocrine reviews, 2019-02-01

Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.

Eur J Endocrinol, 2022 Apr 21

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

Pediatr Hematol Oncol, 2023 Mar 20

Growth hormone after CNS tumor diagnosis: the fundamentals, fears, facts, and future directions.

Journal of thrombosis and haemostasis : JTH, 2019 Sep 13

Transgender patients and the role of the coagulation clinician.

The Journal of clinical endocrinology and metabolism, 2024 Jan 18

Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories.

Journal of the Endocrine Society, 2022 Dec 02

Perioperative Evaluation and Management of Patients on Glucocorticoids.

Diagnostics (Basel, Switzerland), 2021 Apr 20

Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.

The Journal of clinical endocrinology and metabolism, 2018 May 01

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

The Journal of urology, 2022 Jan 20

Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.

Haematologica, 2009 Oct 14

Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.

American journal of hematology, 2023 Jul 20

Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases.

Pediatric Hematology/Oncology

Endocrinology

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology